GHB16L2

AVIR Green Hills Biotechnology AG · Phase 1 active Biologic

At a glance

Generic name	GHB16L2
Sponsor	AVIR Green Hills Biotechnology AG
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GHB16L2 CI brief — competitive landscape report
GHB16L2 updates RSS · CI watch RSS
AVIR Green Hills Biotechnology AG portfolio CI